表紙
市場調査レポート

非メラノーマ性皮膚がん : パイプライン分析

Nonmelanomatous Skin Cancer - Pipeline Review, H2 2015

発行 Global Markets Direct 商品コード 213099
出版日 ページ情報 英文 46 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
非メラノーマ性皮膚がん : パイプライン分析 Nonmelanomatous Skin Cancer - Pipeline Review, H2 2015
出版日: 2015年11月30日 ページ情報: 英文 46 Pages
概要

非メラノーマ性皮膚がんは、皮膚の外面または上皮層の悪性増殖のことを指します。非メラノーマ性皮膚がんは多くの場合、皮膚の外面から、扁平上皮がんまたは基底細胞がんとして生じます。累積的な日光曝露が非メラノーマ性皮膚がんの重大なリスク要因と考えられています。幼児期に大量の日光を浴びてひどい日焼けになったことが、非メラノーマ性皮膚がんの発症に重要な役割を果たす、と示唆する証拠も存在します。基底細胞がんが最も多く発症する場所は顔面部の皮膚で、次いで耳・手の甲・肩・腕となっています。また、男性・女性とも平等に発症し、また40歳以上の人々が最も多く発症します。

当レポートでは、世界各国での非黒色腫性(非メラノーマ性)皮膚がん治療用のパイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要(製品概要、機能メカニズム、研究開発(R&D)の進展状況)、最新の業界動向などを調査して、その結果をお届けします。

イントロダクション

  • 分析範囲

非メラノーマ性皮膚がんの概要

治療薬の開発

  • 非メラノーマ性皮膚がん向けパイプライン製品:概要
  • 非メラノーマ性皮膚がん向けパイプライン製品:比較分析

各企業で開発中の非メラノーマ性皮膚がん治療薬

大学/研究機関で研究中の非メラノーマ性皮膚がん治療薬

パイプライン製品の概略

  • 治験段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

非メラノーマ性皮膚がん治療薬:開発中の製品の一覧(企業別)

非メラノーマ性皮膚がん治療薬:研究中の製品の一覧(大学/研究機関別)

非メラノーマ性皮膚がん治療薬の開発に従事している企業

  • Advancell
  • EcoBiotics Limited
  • Hexima Limited
  • LEO Pharma A/S
  • Spherium Biomed S.L.

非メラノーマ性皮膚がん:治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 機能メカニズム別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • ANS-401
  • ANS-403
  • EBC-46
  • OXT-328
  • 非メラノーマ性皮膚がん向けペプチド
  • 皮膚科学・免疫学・腫瘍学向け組み換え型ペプチド
  • 皮膚科学・腫瘍向けタンパク質キナーゼC 活性化小分子
  • 扁平上皮がん向け PLK1 阻害小分子
  • SP-12054
  • HPV関連の皮膚癌ワクチン

非メラノーマ性皮膚がん治療薬:最新の薬剤プロファイル

非メラノーマ性皮膚がん治療薬:開発が休止状態の製品

非メラノーマ性皮膚がん治療薬:開発が中止された製品

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7358IDB

Summary

Global Markets Direct's, 'Nonmelanomatous Skin Cancer - Pipeline Review, H2 2015', provides an overview of the Nonmelanomatous Skin Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Nonmelanomatous Skin Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nonmelanomatous Skin Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Nonmelanomatous Skin Cancer
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Nonmelanomatous Skin Cancer and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Nonmelanomatous Skin Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Nonmelanomatous Skin Cancer pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Nonmelanomatous Skin Cancer
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Nonmelanomatous Skin Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Nonmelanomatous Skin Cancer Overview
  • Therapeutics Development
    • Pipeline Products for Nonmelanomatous Skin Cancer - Overview
    • Pipeline Products for Nonmelanomatous Skin Cancer - Comparative Analysis
  • Nonmelanomatous Skin Cancer - Therapeutics under Development by Companies
  • Nonmelanomatous Skin Cancer - Therapeutics under Investigation by Universities/Institutes
  • Nonmelanomatous Skin Cancer - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Nonmelanomatous Skin Cancer - Products under Development by Companies
  • Nonmelanomatous Skin Cancer - Products under Investigation by Universities/Institutes
  • Nonmelanomatous Skin Cancer - Companies Involved in Therapeutics Development
    • Advancell
    • EcoBiotics Limited
    • Hexima Limited
    • LEO Pharma A/S
    • Spherium Biomed S.L.
  • Nonmelanomatous Skin Cancer - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ANS-40 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ANS-401 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ANS-403 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • EBC-46 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OXT-328 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Peptide for Non-Melanoma Skin Cancer - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Peptide for Dermatology, Immunology and Oncology - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Activate Protein Kinase C for Dermatology and Cancer - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit PLK1 for Cutaneous Squamous Cell Carcinoma - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SP-12054 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine for HPV Associated Skin Cancer - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Nonmelanomatous Skin Cancer - Recent Pipeline Updates
  • Nonmelanomatous Skin Cancer - Dormant Projects
  • Nonmelanomatous Skin Cancer - Discontinued Products
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Nonmelanomatous Skin Cancer, H2 2015
  • Number of Products under Development for Nonmelanomatous Skin Cancer - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Comparative Analysis by Unknown Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Investigation by Universities/Institutes, H2 2015
  • Nonmelanomatous Skin Cancer - Pipeline by Advancell, H2 2015
  • Nonmelanomatous Skin Cancer - Pipeline by EcoBiotics Limited, H2 2015
  • Nonmelanomatous Skin Cancer - Pipeline by Hexima Limited, H2 2015
  • Nonmelanomatous Skin Cancer - Pipeline by LEO Pharma A/S, H2 2015
  • Nonmelanomatous Skin Cancer - Pipeline by Spherium Biomed S.L., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Nonmelanomatous Skin Cancer Therapeutics - Recent Pipeline Updates, H2 2015
  • Nonmelanomatous Skin Cancer - Dormant Projects, H2 2015
  • Nonmelanomatous Skin Cancer - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Nonmelanomatous Skin Cancer, H2 2015
  • Number of Products under Development for Nonmelanomatous Skin Cancer - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Targets, H2 2015
  • Number of Products by Stage and Targets, H2 2015
  • Number of Products by Mechanism of Actions, H2 2015
  • Number of Products by Stage and Mechanism of Actions, H2 2015
  • Number of Products by Routes of Administration, H2 2015
  • Number of Products by Stage and Routes of Administration, H2 2015
  • Number of Products by Molecule Types, H2 2015
  • Number of Products by Stage and Molecule Types, H2 2015
Back to Top